Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer

Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer

Show other versions (1)

Aim: to compare the immunoexpression of BRAF V600E among stage of colorectal cancer. Methods: this was a cross sectional, and retrospective study involving Dukes’ stage A, B, and C colorectal carcinoma, each with 15 cases. Immunohistochemistry was performed in paraffin-embedded specimens of tumor m...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bethy S Hernowo, Fenny Ariyanni, Sri Suryanti, Abdul H Hassan
Format:	Article
Language:	English
Published:	Interna Publishing 2016-05-01
Series:	Acta Medica Indonesiana
Online Access:	https://www.actamedindones.org/index.php/ijim/article/view/75
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer
by: Bethy S Hernowo, et al.
Published: (2016-05-01)

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-03-01)

Correction: Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-04-01)

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations
by: J. Ros, et al.
Published: (2025-09-01)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
by: Jennifer A. Silver, et al.
Published: (2021-11-01)

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab
by: Toru Imai, et al.
Published: (2024-12-01)

Comparision Of BRAF V600E, COX–2 and p53 As Biomarkers For The Early Detection Of Colorectal Cancer
by: Hina Wasti, et al.
Published: (2019-06-01)

Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues.
by: Nunthawut Chat-Uthai, et al.
Published: (2018-01-01)

Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers
by: Pawel Sadlecki, et al.
Published: (2017-05-01)

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆
by: G.K. In, et al.
Published: (2024-12-01)

Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells
by: Girolamo Spagnoletti, et al.
Published: (2018-04-01)

THE ROLE OF BRAF V600E IN THE DEVELOPMENT OF THYROID CANCER PHENOTYPE: A SYSTEMATIC REVIEW
by: Pratia Mega, et al.
Published: (2025-01-01)

Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
by: Michael Hoffmeister, et al.
Published: (2025-02-01)

Prospects of BRAF/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review
by: Shingo FUJIO, et al.
Published: (2025-05-01)

Introduction and expression of PIK3CA E545K in a papillary thyroid cancer BRAF V600E cell line leads to a dedifferentiated aggressive phenotype
by: Nicole Pinto, et al.
Published: (2022-02-01)

Clinical impact of first-line therapeutic strategies in BRAF V600E-mutant metastatic colorectal cancer: real-world evidence and prognostic insight
by: Chia-Chang Yeh, et al.
Published: (2025-07-01)

Case report: a rare case of diffusely metastatic BRAF V600E-mutated colorectal cancer with concomitant infiltration of the skin and parotid gland
by: Aristeidis E. Boukouris, et al.
Published: (2025-01-01)

Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report
by: Qun Zhang, et al.
Published: (2025-12-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01)

Transsulfuration Reprogramming: A Metabolic Driver of BRAF‐V600E Resistance in Melanoma
by: Juntong Chen, et al.
Published: (2025-06-01)

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors
by: Santosh Sharma, et al.
Published: (2023-08-01)

A multi-center cross-sectional investigation of BRAF V600E mutation in Ameloblastoma
by: Khin Mya Tun, et al.
Published: (2025-04-01)

Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study
by: Aishwariya Mohanty, et al.
Published: (2024-06-01)

BRAF V600E Mutation in Odontogenic Keratocyst: A Systematic Review and Meta-Analysis
by: Jéssica da Silva Cunha, et al.
Published: (2025-01-01)

Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry.
by: Ana Claudia Urvanegia, et al.
Published: (2017-01-01)

Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature
by: Hirra A. Chaudhary, et al.
Published: (2024-08-01)

Insidensi Bayi Berat Lahir Rendah pada Spektrum Plasenta Akreta di Rumah Sakit Dr Hasan Sadikin Bandung
by: Yuktiana Kharisma, et al.
Published: (2022-12-01)

Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E)
by: Md Mohiuddin, et al.
Published: (2025-08-01)

Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study
by: Clara Mayo de las Casas, et al.
Published: (2025-01-01)

Can mutation abundance assess the biological behavior of BRAF V600E-positive papillary thyroid carcinoma?
by: Yeqin Ni, et al.
Published: (2025-07-01)

Postpartum colonic squamous cell carcinoma with a BRAF V600E mutation: a case report
by: Qin Wang, et al.
Published: (2025-08-01)

BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report
by: Yufei Liu, et al.
Published: (2025-02-01)

Resistance to MAPK Pathway Inhibition in <i>BRAF</i>-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors
by: Layla El Bouazzaoui, et al.
Published: (2025-06-01)

Immunohistochemical Study Using Monoclonal VE1 Antibody Can Substitute the Molecular Tests for Apprehension of BRAF V600E Mutation in Patients with Non-small-Cell Lung Carcinoma
by: Hadeel Abdul Elah Karbel, et al.
Published: (2019-01-01)

TREATMENT OF <em>BRAF</em><sup>V600E</sup> POSITIVE ANAPLASTIC THYROID CARCINOMA: CASE REPORT
by: P. A. Nikiforovich, et al.
Published: (2020-10-01)

COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
by: Ada Ndoja, et al.
Published: (2025-06-01)

The prevalence of BRAF V600E mutation in hairy cell leukemia: A systematic review and meta-analysis study
by: Mehrdad Payandeh, et al.
Published: (2019-01-01)

Loss of the chromatin modifier Kdm2aa causes BrafV600E-independent spontaneous melanoma in zebrafish.
by: Catherine M Scahill, et al.
Published: (2017-08-01)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
by: Takuji Seo, et al.
Published: (2020-01-01)